Forty Seven to Present at Upcoming Investor Conferences in February
06 Febbraio 2020 - 2:00PM
Forty Seven, Inc. (Nasdaq:FTSV), a clinical-stage,
immuno-oncology company focused on developing therapies to activate
macrophages in the fight against cancer, today announced its
participation in the following upcoming investor conferences:
- Guggenheim Healthcare Talks | Oncology Day on
Thursday, February 13, 2020 at 11:30 a.m. ET in New York, NY.
- 9th Annual SVB Leerink Global Healthcare
Conference on Tuesday, February 25, 2020 at 11:30 a.m. ET
in New York, NY.
A live webcast of each presentation will be available under
“Events & Presentations” in the Investors section of Forty
Seven’s website at www.fortyseveninc.com. A replay of the webcasts
will be available on Forty Seven’s website for 90 days following
each presentation.
About Forty Seven, Inc.
Forty Seven, Inc. is a clinical-stage immuno-oncology
company that is developing therapies targeting cancer immune
evasion pathways and specific cell targeting approaches based on
technology licensed from Stanford University. Forty Seven’s
lead program, magrolimab, is a monoclonal antibody against the CD47
receptor, a “don’t eat me” signal that cancer cells commandeer to
avoid being ingested by macrophages. This antibody is currently
being evaluated in multiple clinical studies in patients with
myelodysplastic syndrome, acute myeloid leukemia and non-Hodgkin’s
lymphoma.
For more information please visit www.fortyseveninc.com or
contact info@fortyseveninc.com.
For journalist enquiries please contact Sarah Plumridge at
fortyseven@hdmz.com or phone (312) 506-5218.
For investor enquiries please contact Hannah Deresiewicz at
Stern Investor Relations Inc. at hannah.deresiewicz@sternir.com or
phone (212) 362-1200.
Grafico Azioni Forty Seven (NASDAQ:FTSV)
Storico
Da Giu 2024 a Lug 2024
Grafico Azioni Forty Seven (NASDAQ:FTSV)
Storico
Da Lug 2023 a Lug 2024
Notizie in Tempo Reale relative a Forty Seven Inc (NASDAQ): 0 articoli recenti
Più Articoli Notizie